Analysis on the Risk Management of the Large Volume Infusion Solution

[1]

MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.

[2]

YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin. Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.

[3]

ZHU Yuanchao, ZHANG Yatong, HU Xin. Principles and measures of medication risk management in the elderly [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1031-1034.

[4]

SONG Mingyue, ZHANG Ran, WU Zhiang. Influencing factors of quality risk management of drug recall in China [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1087-1090.

[5]

ZHENG Mingjie, ChENG Rong, SONG Haibo. Bibliometric Analysis of Pharmacovigilance Research in China [J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 686-688.

[6]

FAN Yan, WANG Dan, WANG Chunting. The Mechanism of Toxicity Reaction Induced by Protamine Sulfate Injection [J]. Chinese Journal of Pharmacovigilance, 2021, 18(12): 1159-1161.

[7]

XUE Wei, QI Wenyuan, LIU Yue, CONG Duanduan, LIU Xiaohui, LI Hongyan, WANG Juan, LI Kexin, HU Xin. Design and Implementation of Bioequivalence Tests Based on Risk Management Strategies [J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 549-552.

[8]

[9]

WEI Fuqian, ZHANG Wei, YANG Yue. Implementation of US FDA's Drug Risk Evaluation and Mitigation Strategies [J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 871-876.

[10]

ZHANG Rui, PAN Yan, WU Zhiang. Quality Risk Management during Implementation of Phase Ⅱa Clinical Trials of Innovative Anti-tumor Drugs [J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 886-889.

[11]

ZOU Limin, QI Yueli, TANG Ling, DU Yu, YANG Zhimin. How to Develop a Post-marketing Risk Management Plan for New Drug Applications in Line with E2E Guidelines [J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 780-784.

[12]

SANG Yuan, WU Shifu, LU Changfei, XIE Yanjun, CUI Xiaokang, XU Lili, LIU Wenwen, HUO Yanfei. Problems and Thoughts on Reporting and Monitoring of Adverse Drug Reactions in Drug Manufacturers [J]. Chinese Journal of Pharmacovigilance, 2019, 16(4): 215-218.

[13]

ZOU Limin, QI Yueli, TANG Ling, YANG Zhimin. Post-marketing Risk Management of New Drugs in China Inspired by E2E Guidelines [J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 670-674.

[14]

DING Faming, ZHANG Xinli, WANG Qiong, YIN Maoshan. Preliminary Discussion on the Risk Management of QT-prolonging Drugs Use and Its Implication [J]. Chinese Journal of Pharmacovigilance, 2018, 15(9): 545-549.

[15]

Endocrinology and Metabolism Branch of Chinese Association of Geriatric Research, Committee of Clinical Toxicology of Chinese Society of Toxicology. Expert Consensus on Risk Management of Polypharmacy in Elderly [J]. Chinese Journal of Pharmacovigilance, 2018, 15(10): 627-640.

PDF (PC)